Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in biosimilars & generics will be read downstream.
Biosimilars & Generics
ICG works across biosimilar and generic markets where entry timing, filing strategy, manufacturing readiness, supply, contracting, channel behavior, and originator response must be reconstructed together.
The work includes biosimilar competitive intelligence, generic-entry scenarios, regulatory and patent-pathway assessment, API and manufacturing analysis, tender and contracting architecture, commercialization, and longitudinal monitoring.
Entry Is a System, Not a Date.
Loss of exclusivity does not create a single market event. Entry depends on filing pathways, litigation, manufacturing, formulation, interchangeability, tenders, channel incentives, supply reliability, and the defensive choices of incumbents.
ICG reconstructs the sequence and interaction of those conditions to show how competitive pressure is likely to form, where it may stall, and which assumptions govern commercial exposure.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across biosimilars & generics.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Entry & Regulatory Pathways
- Longitudinal Development and Launch Monitoring of Biosimilars Across Oncology and Immunology in Europe
- Longitudinal Generic-Entry Monitoring for an Intravenous Anti-Infective in Europe
- Regulatory Submission Strategy for Generic Ferric Carboxymaltose in France and the European Union
- European Market-Entry Assessment for Complex Injectable Iron Generics
- Regulatory Filing Architecture for Complex Hospital Generics in the United States and Europe
- Generic-Entry Scenarios for ADHD in the United States
Manufacturing & Supply
- Biosimilar API, Clinical-Trial and Manufacturing-Supply Architecture
- Manufacturing and Supply Assessment for Pegfilgrastim Biosimilars in Europe
- Cell-Line and Phase III Readiness Assessment for Adalimumab Biosimilars
- Manufacturing-Capability Assessment for Rituximab and Trastuzumab Biosimilars
- Supply-Chain Architecture for Generic Anti-Infectives in Europe and Asia
- Cost and Manufacturing Assessment for Pancreatic-Enzyme Replacement Generics
Pricing, Contracting & Channels
- Pharmacy-Price Architecture for Generic Tapentadol in Germany
- Tender and Contracting Architecture for Biosimilars in Europe
- Payer and Channel Response to Biosimilar Entry in Specialist Markets
- Generic Floor-Price and Entry-Price Architecture Across Selected Markets
- Competitive and Contracting Architecture for Biosimilars in Emerging Markets
- Specialty-Pharmacy and Distribution Strategy for Complex Generics in the United States
Launch & Organization
- Launch Architecture for a Natalizumab Biosimilar in the United States, Europe and Brazil
- Originator Defense and Biosimilar-Entry Strategy for an Anti-TNF Therapy
- Commercial Organization for Biosimilar Launches Across Selected European Markets
- Cross-Market Biosimilar Entry Assessment in Turkey, Korea and Latin America
- Field-Force and Account-Coverage Benchmarking for Biosimilar Portfolios
Longitudinal Monitoring & Portfolio
- Ten-Year Competitive Monitoring Program for Biosimilars Across Europe
- Longitudinal Generic-Entry Monitoring for a Leading Dry-Eye Therapy in the United States
- Multi-Market Generic-Entry, Device and Specialty-Pharmacy Strategy for Multiple Sclerosis
- Longitudinal Competitive Monitoring of Pegfilgrastim Biosimilars in Europe
- Multi-Year Generic-Entry Monitoring Across Pulmonary-Hypertension Therapies in Europe and Asia
Biosimilars & Generics Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.